VioQuest Appoints Pharma Veteran Vice President of Corporate Business Development
Posted on: Tuesday, 19 July 2005, 09:00 CDT
VioQuest Pharmaceuticals, Inc. (VQPH) has appointed Richard J. Welter, Ph.D. its new Vice President of Corporate Business Development.
"We are thrilled to announce the addition of Dr. Richard Welter as Vice President of Corporate Business Development," commented VioQuest President and CEO, Daniel Greenleaf. "Dick's appointment plays a significant role in building the Company's senior management team. As we move into developing our therapeutic business - furthering the development of the two promising anti-cancer compounds that we will acquire in our proposed acquisition, we believe Dick's 25 plus years of pharmaceutical experience will both enhance our current development programs, and facilitate significant diversification and rapid expansion of our therapeutics portfolio. His impressive background in business development, along with his vast industry network, will also be extremely valuable in fueling the growth of our chiral business."
Prior to joining VioQuest, Dr. Welter served as Vice President of Business Development at Vela Pharmaceuticals, where he was responsible for leading all licensing and business development activities, including the direction and coordination of financial, marketing, legal, and regulatory evaluations of compound opportunities. His past experience in the pharmaceutical industry includes 24 years of service with Pharmacia Corporation (and its heritage companies, beginning at Upjohn), where he last served as Executive Director of Global Licensing. While at Pharmacia, Dr. Welter evaluated and pursued licensing and marketing opportunities for products and compounds for use in human medicine, as well as formulating strategies for product licensing and acquisition. Dr. Welter received his B.S. in Biology from Creighton University and his Ph.D. in Genetics from Iowa State University. He has also served as an Assistant Professor at both Iowa State University and the University of Northern Iowa.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc. strategy is to acquire and develop late preclinical and early clinical-stage therapies for oncological, viral and autoimmune diseases. The Company recently entered into a definitive merger agreement to acquire Greenwich Therapeutics, which owns exclusive license rights to two anti-cancer agents - sodium stibogluconate (SSG) and triciribine (TCN-P). VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improve the safety and efficacy of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to twelve of the top eighteen pharmaceutical companies at all stages of product life cycles to pharmaceutical and fine chemical manufacturers worldwide. For more information please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements.
Source: Business Wire
Related Articles
- HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University
- Six Products of Telestone Have Been Selected into 'The 3rd Catalog of the Self-Developed Products in Beijing City'
- Urbancode and Klocwork Deliver Solution to Enable Improved Developer Productivity
- Saft and ESMA to Cooperate on Supercapacitor Development, Production and Commercialization
- LCL Completes Acquisition of Universal Freight Forwarders, Ltd.
- Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
- TrendSetter Solar Products Contributes to Santa Clara University's Success In ``Solar Decathlon 2007''
- Simulations Plus Receives Multi-Year Pharmaceutical Software License; Large Pharmaceutical Company Renews Multi-Year License
- Pharmaceutical Companies Look to Biomarkers to Help in Increasing Research and Development Productivity Rates
- Cornerstone BioPharma, Inc. Acquires EXTENDRYL Family of Products From FLEMING & COMPANY, Pharmaceuticals
 |
 |
User Comments (0)
RSS Feeds